JPMorgan Chase & Co. downgraded shares of Endologix (NASDAQ:ELGX) from a neutral rating to an underweight rating in a report issued on Tuesday, Marketbeat reports.
Several other brokerages also recently issued reports on ELGX. Piper Jaffray Companies reiterated an overweight rating on shares of Endologix in a report on Tuesday, December 12th. Royal Bank of Canada decreased their price target on Endologix from $5.00 to $4.00 and set a sector perform rating for the company in a report on Wednesday, November 8th. Canaccord Genuity reiterated a hold rating and set a $5.00 price target on shares of Endologix in a report on Monday, October 9th. Stifel Nicolaus set a $6.00 price target on Endologix and gave the stock a hold rating in a report on Friday, October 6th. Finally, ValuEngine downgraded Endologix from a sell rating to a strong sell rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of $5.41.
Shares of Endologix (NASDAQ:ELGX) opened at $5.12 on Tuesday. Endologix has a 1-year low of $4.08 and a 1-year high of $7.66. The stock has a market capitalization of $434.79, a price-to-earnings ratio of -5.51 and a beta of 0.72. The company has a current ratio of 2.90, a quick ratio of 2.11 and a debt-to-equity ratio of 2.61.
COPYRIGHT VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3128033/jpmorgan-chase-co-downgrades-endologix-elgx-to-underweight.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.